Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Luc CabelMatthieu CartonBianca CheaibJean-Yves PiergaFlorence DalencAudrey MailliezChristelle LevyWilliam JacotMarc DebledMarianne LeheurteurIsabelle DesmoulinsClaudia LefeuvreAnthony GonçalvesLionel UwerJean-Marc FerreroJean-Christophe EymardThierry PetitMarie-Ange Mouret-ReynierGeneviève PerrocheauIrwin PiotDavid PérolGaëtane SimonFlorence LereboursPublished in: Breast cancer research and treatment (2018)
Oral etoposide retains some efficacy in selected heavily pre-treated patients with HER2-negative MBC, with the advantages of oral administration.